SecBot SecBot
PRESS-RELEASE ·Filed Jul 30, 2026

IRON

Disc Medicine Inc
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

Monitor APOLLO topline data in Q4 2026 and RESTORE-PV initial data in Q3 2026 as key catalysts. The FDA alignment reduces regulatory risk for bitopertin, and the accelerated enrollment timeline for DISC-3405 suggests strong investigator interest. Cash runway into 2029 provides ample funding through these milestones.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$79.21
T+0 close · Jul 30, 2026 · via day close
Latest settled
−5.93%
T+60 · $74.51
Vs SPY
−8.40%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $79.21entry
  2. T+1 · 4mo ago −2.79%α −3.50% · $77.00
  3. T+5 · 3mo ago −2.23%α −5.86% · $77.44
  4. T+20 · 3mo ago +4.22%α +0.25% · $82.55
  5. T+60 · 25d ago −5.93%α −8.40% · $74.51
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine reported Q2 2026 net loss of $59.5M ($1.54/share), beating consensus of -$1.77 by 13%. The key catalyst is the completed Type A FDA meeting aligning that the Phase 3 APOLLO trial of bitopertin in EPP, if successful, can serve as the basis for a CRL response, with topline data expected in Q4 2026. The company also completed enrollment for the RESTORE-PV Phase 2 study of DISC-3405, with initial data now expected in Q3 2026, ahead of schedule.

Key Financial Metrics

EPS
−$1.54
est −$1.77 · +13.0%
Revenue
$0.00
est $0.00
Rating
beat

Key Facts

  • Q2 2026 net loss of $59.5M ($1.54/share) vs $55.2M ($1.58/share) in Q2 2025, beating consensus of -$1.77
  • Cash, cash equivalents, and marketable securities of $717.7M as of June 30, 2026, providing runway into 2029
  • Completed Type A meeting with FDA; Phase 3 APOLLO topline data for bitopertin in EPP expected Q4 2026
  • Completed enrollment for RESTORE-PV Phase 2 study of DISC-3405 in polycythemia vera; initial data expected Q3 2026
  • Selcodebart (DISC-0974) received EU Orphan Drug Designation for myelofibrosis; updated RALLY-MF data presented at ASCO/EHA

Financial Impact

Net loss of $59.5M in Q2 2026, slightly wider than $55.2M in Q2 2025; cash burn rate consistent with prior quarter

net losscash positionR&D expenses

Risk Factors

  • Phase 3 APOLLO trial failure would significantly impair bitopertin's regulatory path
  • Clinical-stage biotech with no approved products or revenue; relies on successful pipeline advancement
  • Cash burn rate may increase as multiple programs advance into later-stage trials

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3336047

Track record

43 reports on IRON

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 10 of 15 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (9h 35m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026